1. In Vivo
  2. >>Market Intelligence

Merck Survey Highlights HIV Knowledge Gaps

HIV Misinformation Persists Among Millennials, African Americans

 
• By Ben Comer

New options for the treatment and prevention of HIV/AIDs in recent years have not erased lingering stigmas and misinformation about the disease, especially among younger black communities in the US. Advocates hope that greater awareness of “U=U,” or “undetectable equals untransmittable,” can help to address ongoing discrimination and disparities.

Digital illustration of HIV Virus in Blood Stream in color background
• Source: Shutterstock

Survey data collected as part of Merck & Co., Inc.'s ongoing “Owning HIV” campaign revealed a significant prevalence of serophobia – an aversion to or fear of people with HIV – in the US adult population. However, the Prevention Access Campaign’s undetectable equals untransmittable (U=U) messaging is making inroads among physicians, public health officials and advocates in the HIV/AIDS community around the world.

HIV/AIDS-related disparities and stigma among younger individuals identifying as black or African American persist, according to the Merck survey data....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Intelligence

The Goldilocks Isotope: Perspective Therapeutics’ ‘Just Right’ Alpha Radiotherapeutic

 
• By David Wild

Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.

Pharma’s Dance With Trump Risks Distracting From Longer-Term Threats

 
• By Melanie Senior

Industry is trying to side-step President Trump’s tariff- and price-curbing policy proposals. It may do better facing up to enduring R&D productivity and drug affordability challenges.

Tackling Fraud In The UK: Pharma, Are You Ready?

 
• By Trevor Francis

UK pharma faces a critical turning point as the Economic Crime and Corporate Transparency Act introduces the "Failure to Prevent Fraud" offense in September 2025, requiring companies to transform their approach to fraud prevention or face severe consequences.

Finding The Fire: AltruBio’s Novel Approach To Autoimmune Disease

 
• By David Wild

CEO Judy Chou brings big pharma experience to tackle chronic inflammation with the company's first-in-class PSGL-1 targeting therapy.

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By Jo Shorthouse

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.